http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112679610-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate | 2020-12-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-112679610-B |
| titleOfInvention | Human anti-human TIGIT antibody and application thereof |
| abstract | The invention discloses a human anti-human TIGIT antibody and application thereof. The invention discloses an anti-human TIGIT antibody, which contains a heavy chain variable region V H And light chain variable region V L ，V H And V L Both consist of a determinant complementary region and a framework region; v H And V L Each of the determinant complementary regions of (a) consists of a CDR1, a CDR2 and a CDR 3; v H The amino acid sequences of the CDR1, CDR2 and CDR3 of (A) are shown as amino acids at positions 30-35, 50-66 and 99-107 of SEQ ID No. 10; v L The amino acid sequences of the CDR1, CDR2 and CDR3 are shown as amino acids 23 to 33, 49 to 55 and 88 to 96 of SEQ ID No. 9. The antibody disclosed by the invention can be combined with TIGIT (tungsten inert gas) with high affinity, can effectively block the combination of CD155 and TIGIT, and has antitumor activity. |
| priorityDate | 2020-11-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 691.